Analysis of BAI3 as a potential biomarker for lung cancer immunotherapy.

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements vs placebo. In our study, we first of all included 643 patients. We ...

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study At the first overall survival (OS) ...

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...

Merus NV ((MRUS)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending pembrolizumab (Keytruda, Merck Sharp and Dohme) in combination with chemotherapy for women ...

Findings showed Zepzelca with atezolizumab reduced the risk of disease progression or death by 46% and the risk of death by 27% vs atezolizumab alone. The approval was based on data from the ...

Tiragolumab plus atezolizumab does not improve survival compared to durvalumab in locally advanced, unresectable, stage 3 NSCLC.

Please provide your email address to receive an email when new articles are posted on . The FDA approved the combination of lurbinectedin and atezolizumab as first-line maintenance treatment for ...